Window Therapeutics, Inc.
Boston, MA
- UEI
- JFLXDJ3ZY975
- CAGE
- 8PJX8
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 100 Morrissey Blvd 010 3 187, Boston, MA 02125, USA
- Website
- windowtx.com
- Founded
- 2021
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Senex Biotechnology Inc. | Maynard, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Microquin LTD | Cambridge, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Creative Biotherapeutics LLC | Gurnee, IL | — |
| AVM Biotechnology, Inc. | Seattle, WA | — |
| PDX Pharmaceuticals Inc. | Portland, OR | 541713 Research and Development in Nanotechnology |
About the company
Window Therapeutics, Inc. is a biotechnology company located in Boston, Massachusetts, focused on developing advanced antibody-drug conjugate (ADC) technologies for cancer treatment. Registered in SAM.gov since July 2020, the company is a for-profit corporate entity specializing in innovative pharmaceutical research and development, with a particular emphasis on creating next-generation cancer therapies that improve drug delivery and targeting mechanisms.
The company has secured multiple federal grants from agencies like the National Science Foundation and National Cancer Institute to advance its ADC platform technologies. These grants have supported research into developing antibody-drug conjugates with significantly higher drug-to-antibody ratios, ranging from 30 to 90 drugs per antibody, compared to current industry standards of 8. Specific research projects have included developing ADCs for triple negative breast cancer treatment using proteasome inhibitors, creating immunotherapies for colorectal cancer with immunostimulatory payloads, and exploring novel brush polymer technologies to enhance cancer drug delivery. The research aims to create more effective cancer treatments with reduced toxicity by enabling the use of less toxic drugs and improving targeted drug delivery. Window Therapeutics has received funding through programs such as the SBIR Phase I and Phase II grants, with project periods ranging from 12 to 24 months and total award amounts between $256,000 and $1,000,000, demonstrating the federal government's interest in supporting their innovative cancer therapy research.
Quick answers
Is Window Therapeutics, Inc. registered in SAM.gov?
Yes. Window Therapeutics, Inc.'s SAM.gov registration is active through October 21, 2027.
What is Window Therapeutics, Inc.'s most recent federal award?
Window Therapeutics, Inc.'s most recent federal grant award is Sbir phase II: antibody-drug conjugates (adcs) with high drug-antibody ratios (DAR) and molecularly targeted payloads (2423415), from National Science Foundation, on July 15, 2025.
On GovTribe
See Window Therapeutics, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors